DAE HWA Pharmaceutical Co. Ltd Total Liabilities
DAE HWA Pharmaceutical Co. Ltd total liabilities. Based on the latest financial reports, DAE HWA Pharmaceutical Co. Ltd (067080) has total liabilities worth ₩134.61 Billion KRW (≈ $91.23 Million USD) as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check 067080 cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of DAE HWA Pharmaceutical Co. Ltd (2011–2025)
Total liabilities of DAE HWA Pharmaceutical Co. Ltd from 2011 to 2025. This chart illustrates how DAE HWA Pharmaceutical Co. Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore 067080 long-term investment intensity to see how much of total assets are deployed in long-term investments.
DAE HWA Pharmaceutical Co. Ltd Competitors by Total Liabilities
The table below lists competitors of DAE HWA Pharmaceutical Co. Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Borosil Scientific
NSE:BOROSCI
|
India | Rs1.08 Billion |
|
Riverview Bancorp Inc
NASDAQ:RVSB
|
USA | $1.33 Billion |
|
Multicampus Corporation
KQ:067280
|
Korea | ₩83.88 Billion |
|
Consórcio Alfa de Administração S.A
SA:BRGE3
|
Brazil | R$1.11 Billion |
|
IRM ENERGY LTD
NSE:IRMENERGY
|
India | Rs2.99 Billion |
|
Mangata Holding S.A.
WAR:MGT
|
Poland | zł357.91 Million |
|
WTK Holdings Bhd
KLSE:4243
|
Malaysia | RM673.11 Million |
|
ANJI Technology Co. Ltd
TW:6477
|
Taiwan | NT$4.81 Billion |
Liability Composition Analysis (2011–2025)
This chart breaks down DAE HWA Pharmaceutical Co. Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see DAE HWA Pharmaceutical Co. Ltd balance sheet assets.
Liquidity & Leverage Metrics
DAE HWA Pharmaceutical Co. Ltd Total Liabilities Ratios Explained
DAE HWA Pharmaceutical Co. Ltd total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.56 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.67 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.61 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how DAE HWA Pharmaceutical Co. Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for DAE HWA Pharmaceutical Co. Ltd (2011–2025)
The table below shows the annual total liabilities of DAE HWA Pharmaceutical Co. Ltd from 2011 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | ₩131.72 Billion ≈ $89.27 Million |
-1.62% |
| 2024-12-31 | ₩133.89 Billion ≈ $90.73 Million |
-8.25% |
| 2023-12-31 | ₩145.93 Billion ≈ $98.90 Million |
+20.54% |
| 2022-12-31 | ₩121.06 Billion ≈ $82.04 Million |
+23.91% |
| 2021-12-31 | ₩97.70 Billion ≈ $66.21 Million |
+4.98% |
| 2020-12-31 | ₩93.07 Billion ≈ $63.07 Million |
+7.22% |
| 2019-12-31 | ₩86.80 Billion ≈ $58.82 Million |
+1.91% |
| 2018-12-31 | ₩85.17 Billion ≈ $57.72 Million |
-4.00% |
| 2017-12-31 | ₩88.72 Billion ≈ $60.12 Million |
+1.22% |
| 2016-12-31 | ₩87.65 Billion ≈ $59.40 Million |
+37.92% |
| 2015-12-31 | ₩63.55 Billion ≈ $43.07 Million |
-3.07% |
| 2014-12-31 | ₩65.57 Billion ≈ $44.43 Million |
+9.57% |
| 2013-12-31 | ₩59.84 Billion ≈ $40.55 Million |
-13.02% |
| 2012-12-31 | ₩68.80 Billion ≈ $46.62 Million |
-12.46% |
| 2011-12-31 | ₩78.60 Billion ≈ $53.26 Million |
-- |
About DAE HWA Pharmaceutical Co. Ltd
DAE HWA Pharmaceutical Co., Ltd., a pharmaceutical company, produces and supplies pharmaceutical products in South Korea. The company offers drugs for anticancer, antibiotics, antifungal and skin ailment, antivirus, anti-allergosis, hemorrhoids, antidepressant, antiepileptic, psychotropic agent, anti respiratory, anti-inflammatory, analgesic, skeletal muscle relaxants, osteoporosis, anti-arthriti… Read more